Approved in July, lenacapavir for PrEP has tremendous potential to increase access and engagement in the United States, reaching individuals who have been unable to embrace PrEP in its previous formulations. Please join the Choice Agenda and the HIV BLUPrInt team for a deep dive into rolling out lenacapavir (Yeztugo) in the US. Speakers will summarize lessons, preview existing resources, and call for expanded research and practice models that use lenacapavir as a lever to increase HIV prevention access, empowerment, and reach.

Speakers:

Sarit Golub, PhD, MPH, Hunter Alliance for Research & Translation (HART), Hunter College CUNY
Kathrine Meyers, PhD, Aaron Diamond AIDS Research Center (ADARC), Columbia University
Caroline Carnevale, DNP, MPH, AAHIVS, New York Presbyterian
Jenna Eldib, PharmD, New York Presbyterian
Elizabeth Furuya, MPH, Hunter Alliance for Research & Translation (HART), Hunter College CUNY